355 related articles for article (PubMed ID: 34079763)
1. Rac1, A Potential Target for Tumor Therapy.
Liang J; Oyang L; Rao S; Han Y; Luo X; Yi P; Lin J; Xia L; Hu J; Tan S; Tang L; Pan Q; Tang Y; Zhou Y; Liao Q
Front Oncol; 2021; 11():674426. PubMed ID: 34079763
[TBL] [Abstract][Full Text] [Related]
2. Active RAC1 Promotes Tumorigenic Phenotypes and Therapy Resistance in Solid Tumors.
De P; Rozeboom BJ; Aske JC; Dey N
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545340
[TBL] [Abstract][Full Text] [Related]
3. Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase.
Hudson LG; Gillette JM; Kang H; Rivera MR; Wandinger-Ness A
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261690
[TBL] [Abstract][Full Text] [Related]
4. shRNA-induced silencing of Ras-related C3 botulinum toxin substrate 1 inhibits the proliferation of colon cancer cells through upregulation of BAD and downregulation of cyclin D1.
Huang YS; Jie N; Zhang YX; Zou KJ; Weng Y
Int J Mol Med; 2018 Mar; 41(3):1397-1408. PubMed ID: 29286138
[TBL] [Abstract][Full Text] [Related]
5. The Phosphatidylinositol (3,4,5)-Trisphosphate-dependent Rac Exchanger 1·Ras-related C3 Botulinum Toxin Substrate 1 (P-Rex1·Rac1) Complex Reveals the Basis of Rac1 Activation in Breast Cancer Cells.
Lucato CM; Halls ML; Ooms LM; Liu HJ; Mitchell CA; Whisstock JC; Ellisdon AM
J Biol Chem; 2015 Aug; 290(34):20827-20840. PubMed ID: 26112412
[TBL] [Abstract][Full Text] [Related]
6. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
7. Emerging roles of RAC1 in treating lung cancer patients.
Zou T; Mao X; Yin J; Li X; Chen J; Zhu T; Li Q; Zhou H; Liu Z
Clin Genet; 2017 Apr; 91(4):520-528. PubMed ID: 27790713
[TBL] [Abstract][Full Text] [Related]
8. The role of cell division control protein 42 in tumor and non-tumor diseases: A systematic review.
Fu J; Liu B; Zhang H; Fu F; Yang X; Fan L; Zheng M; Zhang S
J Cancer; 2022; 13(3):800-814. PubMed ID: 35154449
[TBL] [Abstract][Full Text] [Related]
9. Identification of potent and novel inhibitors against RAC1: a Rho family GTPase.
Madhukar G; Subbarao N
In Silico Pharmacol; 2022; 10(1):13. PubMed ID: 35928028
[TBL] [Abstract][Full Text] [Related]
10. Silencing Ras-Related C3 Botulinum Toxin Substrate 1 Inhibits Growth and Migration of Hypopharyngeal Squamous Cell Carcinoma via the P38 Mitogen-Activated Protein Kinase Signaling Pathway.
Cheng H; Wang W; Wang G; Wang A; Du L; Lou W
Med Sci Monit; 2018 Feb; 24():768-781. PubMed ID: 29410394
[TBL] [Abstract][Full Text] [Related]
11. [Rac1 promotes the formation of heterotypic cell-in-cell structure].
Hu T; Feng P; Li H; Zhou L; Niu Z; Huang Y; Wang X; Wang C; Liu H; Wu C
Sheng Wu Gong Cheng Xue Bao; 2023 Oct; 39(10):4123-4134. PubMed ID: 37877395
[TBL] [Abstract][Full Text] [Related]
12. RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer.
Tan S; Yi P; Wang H; Xia L; Han Y; Wang H; Zeng B; Tang L; Pan Q; Tian Y; Rao S; Oyang L; Liang J; Lin J; Su M; Shi Y; Liao Q; Zhou Y
Front Oncol; 2020; 10():649. PubMed ID: 32411607
[TBL] [Abstract][Full Text] [Related]
13. Rac1 as a therapeutic anticancer target: Promises and limitations.
Bailly C; Beignet J; Loirand G; Sauzeau V
Biochem Pharmacol; 2022 Sep; 203():115180. PubMed ID: 35853497
[TBL] [Abstract][Full Text] [Related]
14. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Guo Y; Kenney SR; Muller CY; Adams S; Rutledge T; Romero E; Murray-Krezan C; Prekeris R; Sklar LA; Hudson LG; Wandinger-Ness A
Mol Cancer Ther; 2015 Oct; 14(10):2215-27. PubMed ID: 26206334
[TBL] [Abstract][Full Text] [Related]
15. Botulinum Toxin A Upregulates Rac1, Cdc42, and RhoA Gene Expression in a Dose-Dependent Manner: In Vivo and in Vitro Study.
Park TH; Park JH; Chang CH; Rah DK
J Craniofac Surg; 2016 Mar; 27(2):516-20. PubMed ID: 26963302
[TBL] [Abstract][Full Text] [Related]
16. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.
Baugher PJ; Krishnamoorthy L; Price JE; Dharmawardhane SF
Breast Cancer Res; 2005; 7(6):R965-74. PubMed ID: 16280046
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of RAC1 and VASP gene expression inhibits breast cancer cell migration.
Tian Y; Xu L; He Y; Xu X; Li K; Ma Y; Gao Y; Wei D; Wei L
Oncol Lett; 2018 Aug; 16(2):2151-2160. PubMed ID: 30008913
[TBL] [Abstract][Full Text] [Related]
18. POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1.
Martínez-López A; García-Casas A; Infante G; González-Fernández M; Salvador N; Lorente M; Mendiburu-Eliçabe M; Gonzalez-Moreno S; Villarejo-Campos P; Velasco G; Malliri A; Castillo-Lluva S
Mol Oncol; 2024 Mar; 18(3):620-640. PubMed ID: 38098337
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Yin L; Qiao G; Li Y; Li B; Bai Y; Feng F
Oncol Lett; 2020 Sep; 20(3):2997-3005. PubMed ID: 32782617
[TBL] [Abstract][Full Text] [Related]
20. The role of small GTPases of the Rho/Rac family in TGF-β-induced EMT and cell motility in cancer.
Ungefroren H; Witte D; Lehnert H
Dev Dyn; 2018 Mar; 247(3):451-461. PubMed ID: 28390160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
